

Time	Topic	Speaker	Moderator
17:00 – 17:50	Oral Presentation		
TBCS-GBCC Joint Session			
Theme: Overcome the gap between the reality and international guideline: Taiwan's view and Korea's view			
18:00 – 18:10	Opening	Shou-Tung Chen / Ling-Ming Tseng	
18:10 – 18:40	Korea's view	Ai Ri Han	
18:40 – 19:10	Taiwan's view	Hsu-Huan Chou	
19:10 – 20:10	Round table discussion	Domestic reimbursement regulation vs international treatment guideline	Chi-Cheng Huang Young-Joon Kang
		Lag between the availability on domestic market vs the approval of new drug by USFDA/EMA	Chun-Yu Liu Kyong Hwa Park
		Safety profile information and clinical experience	Hung-Wen Lai Kyung-Hun Lee
		New drug clinical trial accessibility	Fang-Ming Chen Inhae Park
20:10 – 20:20	How to cooperate to empower our voice	Fang-Ming Chen Inhae Park Shin-Cheh Chen Chiun-Sheng Huang Yen-Shen Lu Ling-Ming Tseng	Shin-Cheh Chen Chiun-Sheng Huang Yen-Shen Lu Ai Ri Han Kyong Hwa Park Young-Joon Kang
20:20 – 20:30	Closing	Ling-Ming Tseng	

Taipei International Breast Cancer Symposium 2022

7F, Taipei Nangang Exhibition Center, Hall 2

Sat., October 1, 2022

Time	Topic	Speaker	Moderator
08:15-08:30	Opening Remark	Shou-Tung Chen	
		Pi-Sheng Wang	
08:30-09:00	What can we contribute to breast cancer in Taiwan?	Mien-Chie Hung	King-Jen Chang Hong-Tai Chang
09:00-09:30	Genetic testing for hereditary breast cancer - what we've learned today and what to do tomorrow in Taiwan?	Wen-Ling Kuo	Yuan-Ching Chang Chia-Herng Yue
09:30-10:00	To whom should adjuvant PARP inhibitors be offered?	Charles E. Geyer	Chiun-Sheng Huang Hung-Wen Lai
10:00-10:30	Coffee Break		
10:30-11:00	The changing treatment landscape for HR+HER2-mBC patient with CDK4/6i	Dejan Juric	Ling-Ming Tseng Yi-Fang Tsai
11:00-11:30	Treatment options with CDK4&6inhibitor, S-1, and PARP-inhibitor for HR-positive HER2-negative early breast cancer: Japan experience	Hiroko Masuda	King-Jen Chang Guo-Shiou Liao
Educational Section (1) Management of special subtype			
11:30-11:50	Mucinous carcinoma of the breast	Yoon-Sim Yap	Wen-Hung Kuo Chih-Chiang Hung
11:50-12:20	Metaplastic carcinoma of breast: biology, challenges, and strategic direction	Ching-Hung Lin	Chen-Hsiang Chang Yao-Jen Chang
Satellite Symposium (1)			
12:20-13:00	Luncheon Symposium Thinking outside of the box? What are the possible options for metastatic breast cancer	Wei-Wu Chen	Tsu-Yi Chao Kuo-Ting Lee
13:00-13:30	Break		
13:30-14:00	Maximizing clinical benefit of atezolizumab in triple negative breast cancer	Chun-Yu Liu	Ming-Shen Dai Dah-Cherng Yeh
14:00-14:30	The benefit of extended adjuvant therapy in HER2+ eBC patients with high recurrence risk	Diana Lüftner	Fang-Ming Chen Ta-Chung Chao
14:30-15:00	New horizon of TNBC: clinical outcomes and perspective of A Novel Trop-2 Antibody-Drug conjugate	Hope S. Rugo	Yen-Shen Lu Chiao Lo
15:00-15:30	Coffee Break		
State of the art for luminal disease management			
15:30-16:00	Raising the bar for patients with HR+/HER2- Early Breast Cancer	Nadia Harbeck	Chiun-Sheng Huang Ming-Yang Wang
16:00-16:30	Unsolved questions in CDK4/6i mBC setting	Fatima Cardoso	Shin-Cheh Chen Chieh-Han Chuang
Treatment of HER2 disease			
16:30-17:00	HER2 dual blockade treatment benefit on eBC patient survival and Singapore experience with FlexCare	Soo-Chin Lee	Shyr-Ming Sheen-Chen Shih-Che Shen
17:00-17:30	Past, present and future of HER2+ breast cancer treatment	Paul Cornes	Liang-Chih Liu Chung-Chin Yao

Taipei International Breast Cancer Symposium 2022

7F, Taipei Nangang Exhibition Center, Hall 2

Sun., October 2, 2022

Time	Topic	Speaker	Moderator
Local-regional treatment			
08:20-08:50	Local-regional management after neoadjuvant therapy—surgeon’s view	Laura Dominici	Jyh-Cherng Yu Huan-Ming Hsu
08:50-09:20	Local therapy for the primary site in De Novo Stage IV breast cancer	Seema A. Khan	Dar-Ren Chen Shih-Hsin Tu
Novel cancer therapy			
09:20-09:50	Recent progress of antibody-drug conjugate in breast cancer treatment	Shanu Modi	Kun-Ming Rau Chia-Ming Hsieh
09:50-10:20	Recent advances in HER2 directed therapy in HER2 positive advanced breast cancer	Soo-Chin Lee	Ming-Feng Hou Ming-Hsin Yeh
10:20-10:40	Coffee Break		
10:40-11:10	Experience sharing: how do we initiate and conduct large scale IIT	Jee Hyun Kim	Hsien-Kun Chang Chun-Yu Liu
Satellite Symposium (2)			
11:10-11:40	Identify unmet needs for improving care for patients with chemotherapy-induced neutropenia	Chi-Cheng Huang	Shou-Tung Chen Yuan-Chiang Chung
11:40-12:10	New strategic approach of neoadjuvant in early breast cancer	Chin-Sheng Hung	Yao-Lung Kuo Chao-Ming Hung
12:10-12:50	Luncheon Symposium Recent roles of vacuum assisted breast biopsy in Korea	Sang-Won Kim	Fiona Tsui-Fen Cheng Frank Fu Ou-Yang
12:50-13:10	Break		
Educational Section (2) Management of specific metastatic site			
13:10-13:40	Bone-targeted agents for the management of breast cancer patients with bone metastases	Dwan-Ying Chang	Hsien-Tang Yeh Tsen-Long Yang
13:40-14:00	Pseudocirrhosis: a unique presentation of liver metastasis in advanced breast cancer	Wei-Li Ma	Cheng-Ping Yu Zhi-Jie Hong
14:00-14:20	Coffee Break		
Educational Section (3) Neoadjuvant treatment			
14:20-14:50	Neoadjuvant chemotherapy backbone, which is the optimal option?	Sibylle Loibl	Ming-Feng Hou Chi-Cheng Huang
14:50-15:20	The considerations about adjuvant treatment choices after neoadjuvant therapy	Giampaolo Bianchini	Shin-Cheh Chen Chien-Liang Liu
15:20-15:50	Avoiding breast and axillary surgery after neoadjuvant therapy	Joerg Heil	Shen-Liang Shih Chin-Yao Lin
15:50-16:20	Adjuvant radiotherapy after neoadjuvant treatment	Boon H. Chua	Sung-Hsin Kuo Chin-Hua Tsai
16:20-16:40	Panel Discussion	Sibylle Loibl Giampaolo Bianchini Joerg Heil Boon H. Chua Wei-Pang Chung Jiun-I Lai Yen-Dun Tzeng	Ling-Ming Tseng Ming-Shen Dai
16:40-17:00	Award Ceremony & Closing	Shou-Tung Chen	